Early tirofiban improves functional outcomes in non-DM ischemic stroke patients but not in DMTrial shows stroke treatment effects vary for patients with diabetes

European stroke journal Published July 14, 2026 Study authors: Wang Li, Tao Chunrong, Luo Cong, Chen Yuerong, Zhu Yuyou, Xu Pengfei, Li Rui, Liu Tianlong, Zhang Ch… PubMed ↗ DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that early tirofiban improves functional outcomes in non-DM stroke patients but shows minimal difference in DM patients.

This post-hoc analysis of a randomized controlled trial included 832 patients with acute ischaemic noncardioembolic stroke across 38 centres. The study evaluated early tirofiban infusion following intravenous thrombolysis compared to placebo, focusing on functional outcomes at 90 days.

In the non-DM group, excellent functional outcome (mRS 0-1) was observed in 69.0% of patients receiving tirofiban versus 55.8% in the placebo group (P =.009 for treatment-by-diabetes interaction). In contrast, the DM group showed a minimal difference, with 55.0% and 52.0% achieving excellent outcomes in the tirofiban and placebo groups, respectively.

Safety data noted serious adverse events including sICH within 36 h and any ICH. Mortality in the DM group was higher in the tirofiban arm (6.6%) compared to placebo (2.0%), though this did not reach statistical significance (P =.082).

Due to the post-hoc nature of the analysis, these results are considered hypothesis-generating and have low certainty. The findings suggest that the impact of tirofiban on functional outcomes may vary based on diabetes status, but prospective studies with pre-specified subgroup analyses are required for confirmation.

How this fits prior evidence

How this fits prior evidence: This finding extends previous reports showing tirofiban improves 90-day functional outcomes in patients with an inadequate response to tenecteplase and in non-LVO acute ischemic stroke. It specifically addresses a gap by investigating the interaction between diabetes status and tirofiban efficacy, suggesting that the benefit observed in prior coverage may be less pronounced or absent in patients with diabetes.

When someone suffers an ischemic stroke, doctors must act fast to restore blood flow. One common treatment is tirofiban, a medication given after clot-busting drugs. A study of 832 patients across 38 centers looked at how this specific drug affects recovery for people with and without diabetes.

The results showed a notable difference. For patients without diabetes, those who received tirofiban had a much higher rate of excellent functional outcomes at 90 days compared to those who received a placebo. However, for patients with diabetes, the improvement was much smaller. This suggests that having diabetes might change how the body responds to this specific treatment.

Because this was a post-hoc analysis, meaning researchers looked at the data after the trial was over to find these patterns, the results are currently used to generate new ideas rather than provide firm proof. The study also noted some safety concerns regarding brain bleeds in certain groups. These findings are early and need more focused studies to confirm exactly how doctors should tailor treatment for diabetic patients.

What this means for you:

Tirofiban may improve recovery for stroke patients without diabetes, but the effect is less clear for those with diabetes.

Common questions

Does tirofiban help everyone who has a stroke?

The study found that tirofiban helped many patients without diabetes achieve an excellent functional outcome at 90 days (69.0% compared to 55.8% for placebo). However, the difference was much smaller for patients with diabetes (55.0% vs 52.0%). Because this is a hypothesis-generating study, talk to your doctor about how it applies to you.

Are there any risks associated with tirofiban?

The study tracked serious events like brain bleeds (sICH) within 36 hours and other types of bleeding. While the data showed some variations in mortality rates between groups, these findings are from a post-hoc analysis and require more research to confirm specific safety risks for different patient groups.

How certain are these results regarding diabetes?

The certainty of these results is currently low because the study was a post-hoc analysis, meaning researchers looked at data after the trial ended to find patterns. These findings are intended to generate new ideas for future research rather than providing immediate clinical proof.

Study Details

Study typeRct

Sample sizen = 832

EvidenceLevel 2

PublishedJul 2026

PMID42439414

View Original Abstract ↓

INTRODUCTION: This study aimed to investigate how diabetes mellitus (DM) influences the efficacy of early tirofiban administration after intravenous thrombolysis in patients with acute ischaemic noncardioembolic stroke. PATIENTS AND METHODS: This was a post-hoc analysis of the ASSET-IT (Advancing Stroke Safety and Efficacy through Early Tirofiban Administration after Intravenous Thrombolysis) trial. Patients were categorised into DM and non-DM groups based on baseline diabetes history. The primary efficacy outcome was an excellent functional outcome at 90 days, defined as an mRS score of 0-1. Safety outcomes included sICH within 36 h, any ICH and all-cause mortality within 90 days. The effect of diabetes on treatment outcomes was assessed using multivariable regression models adjusting for relevant confounders. RESULTS: A total of 832 patients at 38 centres were randomised in the ASSET-IT trial (414 to tirofiban, 418 to placebo). The median age was 69 years (IQR, 59-76); 301 (36.2%) were women. Overall, 191 patients (23.0%) had diabetes mellitus. Among patients without diabetes, an excellent functional outcome at 90 days occurred in 69.0% of patients in the tirofiban group and 55.8% in the placebo group, whereas among patients with diabetes, the corresponding rates were 55.0% and 52.0%, respectively. The nominal P value for the treatment-by-diabetes interaction was .009. The 90-day mortality was higher in the DM group receiving tirofiban (6.6% vs 2.0%; RR, 3.79; 95% CI, 0.84-17.05; P = .082) but not in the non-DM group (3.4% vs 4.4%; RR, 0.82; 95% CI, 0.40-1.70; P = .597). CONCLUSION: Exploratory post-hoc findings from the ASSET-IT trial suggest that the association between early tirofiban administration after intravenous thrombolysis and 90-day functional outcomes may differ according to diabetes status. These hypothesis-generating observations require confirmation in prospective studies with pre-specified subgroup analyses.

Early tirofiban improves functional outcomes in non-DM ischemic stroke patients but not in DMTrial shows stroke treatment effects vary for patients with diabetes

How this fits prior evidence

Common questions

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Early tirofiban improves functional outcomes in non-DM ischemic stroke patients but not in DMTrial shows stroke treatment effects vary for patients with diabetes

How this fits prior evidence

Common questions

More on Diabetes

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties